Literature DB >> 25550254

The usefulness of cardiac magnetic resonance in prevention of sudden cardiac death after myocardial infarction.

Esra Gücük İpek1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25550254      PMCID: PMC5336908          DOI: 10.5152/akd.2014.5885

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, I have read with a great interest the article entitled “No association between scar size and characteristics on T-wave alternans in postmyocardial infarction patients with relatively preserved ventricular function presented with non-sustained ventricular tachycardia” by Yalın et al. (1) that was recently published in Anatolian J Cardiol 2014;14: 442-7. The authors have evaluated the relationship between two non-invasive modalities to assess the risk of arrhythmic burden in patients with post-myocardial infarction. They have selected a relatively borderline group with preserved ejection fraction and non-sustained ventricular tachycardia on Holter recordings. In this patient population, we have limited knowledge in assessing the risk of sudden death or guiding the most accurate treatment for prevention. Furthermore, the majority of the trials in the era of prevention of sudden death is based on echocardiography-derived ejection fraction thresholds. Today, we know that cardiac magnetic resonance imaging (MRI) is the gold standard to evaluate myocardial function. Therefore, the article by Yalın et al. (1), emphasizes the need for conducting further studies in this borderline group by using cardiac MRI. Cardiac MRI not only assesses myocardial function and anatomy but also identifies characterization of the tissue and demonstrates viability. Late gadolinium enhancement MRI visualizes the presence of the scar and quantifies the involvement. Proton relaxation times can identify tissue characterization and estimate extracellular volume. T1 and T2 mapping provides information about the edema within the myocardium and assesses the area at risk during acute myocardial infarction (2). Also, perfusion MRI implicates ongoing ischemia or infarction. Those properties may allow selection of the appropriate revascularization strategy and follow-up after treatment (3). Previous studies demonstrated that incorporating MRI findings increased the success of selecting high-risk patients to prevent sudden death. Scar heterogeneity was found to be a predictor of the appropriate implantable cardioverter defibrillator therapy (4). Midwall fibrosis on late gadolinium enhancement MRI was the strongest independent predictor of sudden cardiac arrest in patients with nonischemic and ischemic cardiomyopathy (5). Scar transmurality, as well as post-infarct scar thickness and left ventricular wall thickness measured by MRI, successfully identified inducible sustained ventricular tachycardia (6). Studies have shown that MRI can detect the foci of the arrhythmic sources by depicting transmural scar and peri-infarct zone, which are landmarks for electrophysiological studies. With the use of novel technology, 3-dimensional electroanatomic mapping can be merged with cardiac MRI scar imaging, allowing ablation of the ventricular arrhythmic substrates. Those findings suggest that cardiac MRI will be an indispensable tool in the near future to identify high-risk patients who can benefit from revascularization, defibrillator devices, or ablation of the lethal arrhythmias to prevent sudden death after myocardial infarction.
  6 in total

Review 1.  T1 mapping in ischaemic heart disease.

Authors:  Darach O h-Ici; Sarah Jeuthe; Nadya Al-Wakeel; Felix Berger; Titus Kuehne; Sebastian Kozerke; Daniel R Messroghli
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-02-23       Impact factor: 6.875

2.  Myocardial structural associations with local electrograms: a study of postinfarct ventricular tachycardia pathophysiology and magnetic resonance-based noninvasive mapping.

Authors:  Takeshi Sasaki; Christopher F Miller; Rozann Hansford; Juemin Yang; Brian S Caffo; Menekhem M Zviman; Charles A Henrikson; Joseph E Marine; David Spragg; Alan Cheng; Harikrishna Tandri; Sunil Sinha; Aravindan Kolandaivelu; Stefan L Zimmerman; David A Bluemke; Gordon F Tomaselli; Ronald D Berger; Hugh Calkins; Henry R Halperin; Saman Nazarian
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-11-13

3.  Prevalence of myocardial fibrosis patterns in patients with systolic dysfunction: prognostic significance for the prediction of sudden cardiac arrest or appropriate implantable cardiac defibrillator therapy.

Authors:  Fahad Almehmadi; Sebastien Xavier Joncas; Immaculate Nevis; Mohammad Zahrani; Mahmoud Bokhari; John Stirrat; Nowell M Fine; Raymond Yee; James A White
Journal:  Circ Cardiovasc Imaging       Date:  2014-06-05       Impact factor: 7.792

4.  No association between scar size and characteristics on T-wave Alternans in post-myocardial infarction patients with relatively preserved ventricular function presented with nonsustained ventricular tachycardia.

Authors:  Kıvanç Yalın; Ebru Gölcük; Erhan Teker; Ravza Yılmaz; Memduh Dursun; Ahmet Kaya Bilge; Kamil Adalet
Journal:  Anadolu Kardiyol Derg       Date:  2014-01-01

Review 5.  Cardiac magnetic resonance imaging findings and the risk of cardiovascular events in patients with recent myocardial infarction or suspected or known coronary artery disease: a systematic review of prognostic studies.

Authors:  Hamza El Aidi; Arthur Adams; Karel G M Moons; Hester M Den Ruijter; Willem P Th M Mali; Pieter A Doevendans; Eike Nagel; Simon Schalla; Michiel L Bots; Tim Leiner
Journal:  J Am Coll Cardiol       Date:  2014-01-30       Impact factor: 24.094

6.  Scar heterogeneity on cardiovascular magnetic resonance as a predictor of appropriate implantable cardioverter defibrillator therapy.

Authors:  Hussein Rayatzadeh; Alex Tan; Raymond H Chan; Shalin J Patel; Thomas H Hauser; Long Ngo; Jaime L Shaw; Susie N Hong; Peter Zimetbaum; Alfred E Buxton; Mark E Josephson; Warren J Manning; Reza Nezafat
Journal:  J Cardiovasc Magn Reson       Date:  2013-04-10       Impact factor: 5.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.